Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes

BACKGROUND: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an effective oral antidiabetic agent as both monotherapy and when combined with insulin. Data from three observational studies performed in patients with type 2 diabetes receiving sitagliptin therapy in the routine clinical setting were...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuasa, Shouhei, Sato, Kazuyoshi, Takai, Masahiko, Ishikawa, Masashi, Umezawa, Shinichi, Kubota, Akira, Maeda, Hajime, Kanamori, Akira, Miyakawa, Masaaki, Tanaka, Yasushi, Terauchi, Yasuo, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852779/
https://www.ncbi.nlm.nih.gov/pubmed/27222674
http://dx.doi.org/10.14740/jocmr2540w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852779/
https://www.ncbi.nlm.nih.gov/pubmed/27222674
http://dx.doi.org/10.14740/jocmr2540w

Ejemplares similares